Clinical Trial Update: Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating the effect of dapagliflozin on quality of life in patients with type 2 diabetes in real-world practice has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• FARXIGA (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Diabetes Mellitus Type 2 | Phase 4 | Status: WITHDRAWN